Skip to main content

Table 3 comparison of the published phase II studies using gemcitabine and carboplatin combination as first-line chemotherapy in advanced TCC patients

From: A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium

Study

N

RR (%)

TTP/PFS*(mo)

OS(mo)

Neutrop-enia G3/4%

Anemia G3/4%

Thromboc-ytopenia G3/4%

CrCl < 60 or < 50* (%)

Median Age(y)

PS ≥ 2, ≤ 70%* (%)

visceral mets (%)

Carles15

17

56.3

NR

10

24

18

18

100

69

41*

29

Shannon16

17

58.8

4.6

10.5

70

18

47

77

69

29

59

Bellmunt17

16

44

NR

NR

56

50

63

100

68

13

31

Hoschke18

23

60.8

7.8

15.4

26*

30

48

52

68

21

43

Nogue-Aliguer19

41

56.1

7.2*

10.1

63

54

32

54

66

37*

20

Linardou20

56

36

4.8

7.2

28

18

17

68*

75

46

39

Olivares21

50

56

11*

11.3

42

18

20

NR

69

18*

18

Bamias22

60

38.3

7.6

16.3

52

18

23

22*

69

13

52

this study

41

46.2

7.5*

13.6

37

27

24

20

67

15

27

  1. NR, Not reported